Healthcare · Medical Instruments & Supplies

Intuitive Surgical, Inc.

EXCHANGE: ISRG ·USD ·United States
CEO & Director Mr. David J. Rosa
48 Months —

Price Chart

Last 12 months · daily close · updated after market close
12-Month Chart
— —
— —

Key Metrics

Updated Apr 22, 2026
52 Week Range
427.84 – 603.88
Day Range
460.01 – 491.15
EPS (FWD)
11.43
PE (TTM)
57.34
PE (FWD)
39.49
Div Rate (FWD)
—
Yield (FWD)
—
Short Interest
1.91%
Market Cap
$160.28 B
Prev. Close
451.29

Analyst Consensus

Consensus Rating
BUY
Analysts
30
covering this stock
Mean Target
$591.51
+21.9% vs current
Current Price
$485.10
+7.49% today
12-Month Price Target Range
MEAN TARGET
$591.51
NOW $485.10
LOW TARGET
$378.00
HIGH TARGET
$750.00
Range based on 30 Wall Street analysts covering ISRG.
Recent Analyst Actions — 8 unique firms, latest first
  • Apr 22, 2026 Maintain Leerink Partners Outperform ($622 → $573)
  • Apr 22, 2026 Maintain Baird Outperform (+$575 → $610)
  • Apr 22, 2026 Maintain Piper Sandler Overweight ($620 → $580)
  • Apr 22, 2026 Reiterate BTIG Buy PT $574
  • Apr 15, 2026 Maintain Truist Securities Buy ($650 → $580)
  • Apr 13, 2026 Maintain Mizuho Neutral ($575 → $525)
  • Apr 9, 2026 Maintain Goldman Sachs Buy ($714 → $609)
  • Apr 6, 2026 Maintain Evercore ISI Group In-Line ($550 → $480)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core …
Website
www.intuitive.com ↗
Quarter Revenue YoY Net Income EPS (Diluted) YoY Gross Margin Op. Margin
Q4 2025 Dec 2025 $2.87B +18.8% $794.8M $2.21 +17.6% 66.4% 30.2%
Q3 2025 Sep 2025 $2.51B — $704.4M $1.95 — 66.4% 30.3%
Q2 2025 Jun 2025 $2.44B — $658.4M $1.81 — 66.3% 30.5%
Q1 2025 Mar 2025 $2.25B — $698.4M $1.92 — 64.7% 25.7%
Q4 2024 Dec 2024 $2.41B — $685.7M $1.88 — 68.0% 30.5%

Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.

MetricCurrentForward
EPS—$11.43
Revenue—$10.06 B
P/E57.3439.49
Dividend——
Profit Margin28.38%—
PEG Ratio2.39—
Beta (5Y)1.68—
Rate (FWD)
—
Yield (FWD)
—
Payout Ratio
0.00%
Ex-Div Date
—
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

Latest ISRG Coverage